Spero Therapeutics (SPRO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow

Tebipenem HBr (SPR994) - Oral Carbapenem - Tebipenem HBr's ADAPT-PO Phase 3 trial met its primary endpoint, demonstrating non-inferiority to IV ertapenem in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), with similar safety results [5] - The overall combined response rate in the ADAPT-PO trial was 58.8% for oral tebipenem HBr versus 61.6% for IV ertapenem, a difference of -3.3% [21] - The company plans to submit an NDA for Tebipenem HBr in 2Q21 for the treatment of cUTI [5, 11] - If approved, Tebipenem HBr could address a multi-billion dollar opportunity in cUTI and NTM markets, with no approved branded or generic oral competition in the carbapenem class [6] - The carbapenem market is estimated at $3 billion in the United States alone [51] SPR720 - Oral Therapy for NTM Infections - SPR720 is a potential first oral therapy for non-tuberculous mycobacterial (NTM) infections, with orphan drug designation, and initiation of patient dosing in a Phase 2 study planned by YE20 [5] - More than 75% of NTM patients are non-refractory and lack any approved options to treat NTM [95] SPR206 - Novel Therapy for MDR Gram-Negative Infections - SPR206 is a novel therapy for multidrug-resistant (MDR) Gram-negative infections, with a Phase 1 BAL study planned for 1H21 [5] Financial Status - As of September 30, 2020, the company had $127.244 million in cash, cash equivalents, and marketable securities, funding operations into the first quarter of 2022 [118]